Two International Drug Developers Award $2.5 Million in Thorough QT Studies to eResearchTechnology

Two International Drug Developers Award $2.5 Million in Thorough
QT Studies to eResearchTechnology
Agreements with Europe-based and Japan-based Pharmaceutical Organizations
Continue Trend Toward Implementation of Regulatory Guidance by International
Organizations 


PHILADELPHIA, April 11  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has been
awarded two Thorough QT studies valued at more than $2.5 million in cardiac
safety monitoring and services from a Europe-based top 50 global pharmaceutical
and an expanding Japan-based international drug developer for two compounds in
clinical trials.

The awards cover two significant Thorough QT studies, for which eRT is
providing comprehensive support, including provision of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis.  eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT workflow enabled data handling technology, the
first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards.

"Following by several weeks news of Thorough QT Study agreements from another
Japan-based drug developer and the initial study from the same top 50
Europe-based pharmaceutical referenced in this announcement, these contracts
illustrate the growing trend toward implementation of regulatory guidance
worldwide," said Scott Grisanti, senior vice president of business development
and chief marketing officer at eRT.  "Whether an emerging growth organization
or a top 50 pharmaceutical, drug developers whose primary presence is outside
the U.S. are increasingly turning to eRT to provide critical services for
Thorough QT studies.  eRT's ability to leverage partner agreements with
Clinical Pharmacology Units here and abroad, along with our capability to
provide varying levels of consultation and the capacity to conduct studies in
the U.S. and abroad, provide the flexibility and expertise required for such
organizations to successfully complete these mission critical projects."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  The sponsors may cancel these agreements at their sole discretion.  As
a result, actual results may differ materially from any financial outlooks
stated herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Report on Form 10-K
filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology,

Inc.



Web site:  http://www.ert.com/ 

Copyright